Appointments and Second Opinions

Speak with one of our New Patient Coordinators to schedule an appointment, refer a patient or request a second opinion. In urgent cases, we can typically see new patients within 24 hours.

Contact us
Find Clinical Trials

We sponsor and collaborate on clinical trials that break new ground in pediatric cancer and blood disorder treatment. 

Search Pediatric Cancer and Blood Disorder Clinical Trials
Our Affiliations
HMS Affiliate

Dana-Farber/Boston Children's is a teaching affiliate of Harvard Medical School.

Our Affiliations

Rani E. George, MD, PhD

  • Physician
  • Associate Professor of Pediatrics, Harvard Medical School

Office Phone

  • 617-632-5281

Appointment Phone

  • 888-733-4662 (new)
  • 617-632-3270 (established)

Fax

  • 617-632-4850

General

Treatment Centers

Discipline

Clinical Interests

Neuroblastoma, Oncology

Location

Background

Board Certifications

  • Pediatric Hematology/Oncology

Fellowship

  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology
  • Harvard Medical School, Pathology

Residency

  • Boston Combined Residency Program, Boston Children's Hospital/Boston Medical Center, Pediatrics
  • The Royal Victoria Infirmary

Internships

  • John F. Kennedy Memorial Medical Center

Medical School

  • A. M. Dogliotti College of Medicine, University of Liberia

Biography

Dr George received her MD from the University of Liberia and her PhD from the University of Newcastle-upon-Tyne, UK. She completed clinical training in pediatrics and hematology/oncology at the Royal Victoria Infirmary, Newcastle-upon-Tyne, Boston Children's Hospital and Dana-Farber Cancer Institute. She conducted post-doctoral research at Harvard Medical School and Dana-Farber. Her laboratory focuses on identifying molecular targets in cancer cells that can be translated into novel therapies with special emphasis on the pediatric solid tumor neuroblastoma. The translational research program in her laboratory integrates cancer biology, preclinical drug development and clinical trials targeting molecular aberrations in neuroblastoma and other pediatric solid tumors.

Physician Video